Abstract
Purpose
Promising new therapies for neoplasia include tyrosine kinase receptor antagonists. Tyrosine kinase oncogenes present an appealing anti-tumor drug target since they play an integral role in a variety of cellular responses including cell proliferation and differentiation. We previously demonstrated a high rate of epidermal growth factor receptor (EGFR) expression in advanced-stage thymic epithelial tumors. More recently, we have examined c-KIT (CD117) expression in a similar series of tumors.
Methods
Tumor from 35 patients seen at our institution for treatment of advanced-stage thymoma was available. Twenty thymomas and 15 thymic carcinomas were assessed for c-KIT expression. Tissue sections of tumor were stained immunohistochemically with anti-c-KIT (Oncogene). Either cytoplasmic or membrane staining was considered positive. Appropriate controls were performed. Positive staining for c-KIT was present in 12 tumors (11 thymic carcinomas and 1 thymoma).
Results
In distinction to EGFR, c-KIT is expressed more commonly in thymic carcinomas (73% of carcinomas) than in thymoma (5% of thymomas).
Conclusions
An EGFR negative/c-KIT positive staining pattern is typical of thymic carcinoma, whereas thymomas are generally EGFR positive/c-KIT negative. Possible therapeutic implications of these observations remain to be determined.
Similar content being viewed by others
References
Bonner JA, Ezekiel MP, Robert F et al. (2000) Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies [abstr]. ASCO Program/Proceedings 19:5F. Available from URL: http://www.asco.org/prof/me/html/00abstracts/p/m_5F.htm (accessed 8 November 2000)
Fontanini G, Vignati S, Bigini D et al. (1995) Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 31A:178–183
Gibson PC, Cooper K (2002) CD117 (KIT): a diverse protein with selective applications in surgical pathology. Adv Anat Pathol 9:65–69
Gilhus NE, Jones M, Turley H et al. (1995) Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen. J Clin Pathol 48:447–455
Gill GN, Bertics PJ, Santon JB (1987) Epidermal growth factor and its receptor. Mol Cell Endocrinol 51:169–186
Hayashi Y, Ishii N, Obayashi C et al. (1995) Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Virchows Arch 426:43–50
Henley JD, Koukoulis GK, Loehrer PJ Sr (2002) Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol 128:167–170
Hoffmann T, Hafner D, Ballo H et al. (1997) Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res 17:4419–4425
Issing WJ, Liebich C, Wustrow TP et al. (1996) Coexpression of epidermal growth factor receptor and TGF-alpha and survival in upper aerodigestive tract cancer. Anticancer Res 16:283–288
Issing WJ, Wustrow TP, Heppt WJ (1993) Oncogenes related to head and neck cancer. Anticancer Res 13:2541–2551
Kelloff GJ, Fay JR, Steele VE et al. (1996) Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 5:657–666
Levine GD, Rosai J (1978) Thymic hyperplasia and neoplasia: a review of current concepts. Human Pathol 9:495–515
Longley BJ, Reguera MJ, Ma Y (2001) Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 25:571–576
Marino M, Muller-Hermelink HK (1985) Thymoma and thymic carcinoma. Relation of thymoma epithelial cells to the cortical and medullary differentiation of thymus. Virchows Arch [A] 407:119
Pescarmona E, Pisacane A, Pignatelli E et al. (1993) Expression of epidermal and nerve growth factor receptors in human thymus and thymomas. Histopathology. 23:39–44
Rubin MS, Shin DM, Pasmantier M et al. (2000) Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr), for patients (Pts) with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens [abstr]. ASCO Program/Proceedings 19:1860. Available from URL: http://www.asco.org/prof/me/html/00abstracts/ibt/m_1860.htm (accessed 8 November 2000)
Stanton P, Richards S, Reeves J et al. (1994) Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. Br J Cancer 70:427–433
Takes RP, Baatenburg de Jong RJ, Schuuring E et al. (1998) Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anticancer Res 18:4793–4800
Veale D, Ashcroft T, Marsh C et al. (1987) Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer. 55:513–516
Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241–250
Yang XD, Jia XC, Corvalan JRF et al. (2000) Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer treatment. ASCO Program/Proceedings 19:183. Available from URL: http://www.asco.org/prof/me/html/00abstracts/bmt/m_183.htm (accessed 8 November 2000)
Yang XD, Jia XC, Corvalan JRF et al. (1999) Potent anti-tumor activity of ABX-EGF, a fully human monoclonal antibody to the epidermal growth factor receptor. ASCO Program/Proceedings 18:1766. Available from URL: http://www.asco.org/prof/me/html/00abstracts/bmt/m_183.htm (accessed 8 November 2000)
Acknowledgements
We thank Ms. C. Dodson and Mrs. L. Baldridge for their technical expertise and assistance with immunohistochemical staining.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Henley, J.D., Cummings, O.W. & Loehrer, Sr., P.J. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 130, 222–224 (2004). https://doi.org/10.1007/s00432-004-0545-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-004-0545-z